drugset / Trial / NCT06958484
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment of HCC with high-risk recurrence risk
Timeline
- Start
- 2025-05-01
- Primary completion
- 2026-10-01
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Iparomlimab | Monoclonal antibody | — | — |
| Subject | Tuvonralimab | Monoclonal antibody | — | — |